Fig. 2

E2F7 upregulation is required for TMZ resistance in GBM cells. (A-B) Confirmation of E2F7 overexpression in TMZ-S cells and siRNA knockdown in TMZ-R cells by Western blot. GAPDH served as a loading control (n = 3, *p < 0.05, **p < 0.01). (C-D) IC₅₀ assay indicating different drug responses in cells with varying levels of E2F7 expression after 48 h of treatment with TMZ or Dox (n = 3, *p < 0.05, **p < 0.01). (E) CCK-8 assay indicating the cell viability of indicated cells with or without TMZ treatment (200 µM). The growth inhibition ratio of TMZ is presented on the right panel (n = 6, *p < 0.05, **p < 0.01). (F) Colony formation of indicated cells with or without TMZ treatment (200 µM). The colony number and colony inhibition of TMZ are presented on the right panel (n = 3, *p < 0.05, **p < 0.01). (G) Apoptosis analysis by flow cytometry of indicated cells with or without TMZ treatment (200 µM, 48 h). The apoptosis rate in the indicated groups is presented on the right panel (n = 3, **p < 0.01). (H) Schematic diagram of in vivo experimental process. (I) Representative bioluminescence images (BLI) of the indicated groups taken at 14- and 28-days post-transplantation. The relative BLI quantification is presented on the lower panel (n = 5, **p < 0.01)